HK Inno.N Achieves Dual Wins in Social Media Marketing

HK Inno.N has been recognized for its achievements in social media marketing, winning awards on both YouTube and Instagram.

The company announced on July 24 that its official YouTube channel, Channel Inno.N, and its Instagram account received the grand prize and excellence award, respectively, at the 2026 Social Eye Awards, achieving a dual victory.

Now in its eighth year, the Social Eye Awards is the largest SNS awards ceremony in South Korea, organized by the Korea Internet Professionals Association (KIPFA) under the Ministry of Science and ICT. A panel of over 4,000 business marketing experts and creators evaluated entries across five categories using 15 assessment criteria. This year, a total of 296 companies participated.

Channel Inno.N won the grand prize in the medical and pharmaceutical category, marking its second consecutive year of receiving this honor. The channel was praised for effectively delivering medical and health information through relatable content, ensuring public benefit and content dissemination while providing practical value to viewers.

In the past year, Channel Inno.N recorded a total of 9.75 million views, with the number of 'likes' increasing by 199%, demonstrating active two-way communication between customers and the brand.

Notable content includes the talk series 'Infomentary,' which provides insights into the pharmaceutical industry, the entertainment content 'Circle King Ha-jun,' which experiences health clubs, the interview series 'Inno.N Molraewato' reflecting the brand's philosophy, and recruitment and company performance content 'ㅇㄴㅇ' (Inno.N).

HK Inno.N's official Instagram also received the excellence award in the pharmaceutical category. The account has expanded its engagement with customers by providing editorial content that explains proper medication usage and the new drug development process, leveraging the expertise of the pharmaceutical industry.

A representative from HK Inno.N stated, "We have been working to lower the entry barriers of the complex pharmaceutical and bio industry through content, allowing the brand to establish meaningful relationships with customers. We will continue to create empathetic content that reflects our corporate values and customer needs from HK Inno.N's perspective."

Meanwhile, HK Inno.N is expected to report second-quarter results that fall slightly below market expectations.

According to an iM Securities report, HK Inno.N's consolidated revenue for the second quarter is projected to be 267.2 billion won, with an operating profit of 29.5 billion won. While these figures represent a 2% and 51% increase, respectively, compared to the same period last year, they are below the market consensus of 276.6 billion won in revenue and 31.7 billion won in operating profit.

The report noted that domestic sales of K-Cab are expected to decline slightly due to changes in accounting standards for drug price refunds. However, it is anticipated that increased exports of finished products and royalties from China will largely offset this decline. Additionally, the analysis indicated that the long-term growth momentum remains valid based on K-Cab's entry into the U.S. market and its subsequent pipeline.